Loeb Partners Corp continued to hold its stake in Abbott Laboratories (NYSE:ABT) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 30,700 shares of the healthcare product maker’s stock at the close of the second quarter. Loeb Partners Corp’s holdings in Abbott Laboratories were worth $1,492,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in ABT. Waldron LP increased its holdings in shares of Abbott Laboratories by 41.0% during the first quarter. Waldron LP now owns 10,042 shares of the healthcare product maker’s stock valued at $442,000 after acquiring an additional 2,922 shares in the last quarter. Fisher Asset Management LLC increased its holdings in shares of Abbott Laboratories by 12.6% during the first quarter. Fisher Asset Management LLC now owns 16,656 shares of the healthcare product maker’s stock valued at $740,000 after acquiring an additional 1,862 shares in the last quarter. BTR Capital Management Inc. increased its holdings in shares of Abbott Laboratories by 8.9% during the first quarter. BTR Capital Management Inc. now owns 137,418 shares of the healthcare product maker’s stock valued at $6,103,000 after acquiring an additional 11,268 shares in the last quarter. Profund Advisors LLC increased its holdings in shares of Abbott Laboratories by 25.0% during the first quarter. Profund Advisors LLC now owns 69,149 shares of the healthcare product maker’s stock valued at $3,071,000 after acquiring an additional 13,808 shares in the last quarter. Finally, ProShare Advisors LLC increased its holdings in shares of Abbott Laboratories by 8.7% during the first quarter. ProShare Advisors LLC now owns 1,538,527 shares of the healthcare product maker’s stock valued at $68,326,000 after acquiring an additional 123,779 shares in the last quarter. Institutional investors and hedge funds own 71.50% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Abbott Laboratories (ABT) Position Held by Loeb Partners Corp” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/abbott-laboratories-abt-position-held-by-loeb-partners-corp/1609013.html.

In other news, insider Daniel Gesua Sive Salvadori sold 62,460 shares of the business’s stock in a transaction that occurred on Tuesday, September 26th. The stock was sold at an average price of $52.95, for a total value of $3,307,257.00. Following the transaction, the insider now owns 113,426 shares of the company’s stock, valued at $6,005,906.70. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Sharon J. Bracken sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $49.16, for a total value of $98,320.00. Following the completion of the transaction, the insider now directly owns 28,806 shares in the company, valued at approximately $1,416,102.96. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 333,310 shares of company stock worth $16,857,255. 0.76% of the stock is currently owned by corporate insiders.

Shares of Abbott Laboratories (ABT) opened at 54.34 on Thursday. Abbott Laboratories has a 52-week low of $37.38 and a 52-week high of $54.80. The stock has a market cap of $94.41 billion, a price-to-earnings ratio of 76.11 and a beta of 1.06. The firm has a 50-day moving average price of $51.40 and a 200 day moving average price of $47.64.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, July 20th. The healthcare product maker reported $0.62 EPS for the quarter, topping the consensus estimate of $0.60 by $0.02. The company had revenue of $6.64 billion for the quarter, compared to analyst estimates of $6.63 billion. Abbott Laboratories had a return on equity of 14.43% and a net margin of 4.96%. The firm’s revenue was up 24.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.55 earnings per share. Analysts expect that Abbott Laboratories will post $2.49 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 15th. Shareholders of record on Friday, October 13th will be given a dividend of $0.265 per share. This represents a $1.06 annualized dividend and a yield of 1.95%. The ex-dividend date of this dividend is Thursday, October 12th. Abbott Laboratories’s dividend payout ratio (DPR) is 149.30%.

Several equities analysts have recently issued reports on ABT shares. Zacks Investment Research downgraded shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Tuesday, September 26th. Royal Bank Of Canada restated a “buy” rating and set a $55.00 price objective on shares of Abbott Laboratories in a report on Tuesday. Wells Fargo & Company restated an “outperform” rating and set a $54.00 price objective (up previously from $47.50) on shares of Abbott Laboratories in a report on Friday, June 30th. Barclays PLC restated an “overweight” rating and set a $57.00 price objective (up previously from $52.00) on shares of Abbott Laboratories in a report on Saturday, July 22nd. Finally, TheStreet upgraded shares of Abbott Laboratories from a “c+” rating to a “b” rating in a report on Monday, July 3rd. Seven analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Abbott Laboratories presently has an average rating of “Buy” and a consensus price target of $54.40.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.